Difference between revisions of "Apocrine carcinoma of the breast"

From Libre Pathology
Jump to navigation Jump to search
Line 66: Line 66:
*ER -ve.  
*ER -ve.  
*PR -ve.
*PR -ve.
*Her2 -ve


Notes
Notes
*Salivary gland carcinoma and cutaneous adnexal tumors can show a similar IHC profile.
*Salivary gland carcinoma and cutaneous adnexal tumors can show a similar IHC profile.
*Apocrine carcioma is a non-basal type 'triple negative carcinoma' identified by both morphology and AR positivity<ref>{{Cite journal  | last1 = Tsutsumi | first1 = Y. | title = Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma. | journal = Jpn J Clin Oncol | volume = 42 | issue = 5 | pages = 375-86 | month = May | year = 2012 | doi = 10.1093/jjco/hys034 | PMID = 22450930 }}</ref>.
*Apocrine carcioma can be a non-basal type 'triple negative carcinoma' identified by both morphology and AR positivity<ref>{{Cite journal  | last1 = Tsutsumi | first1 = Y. | title = Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma. | journal = Jpn J Clin Oncol | volume = 42 | issue = 5 | pages = 375-86 | month = May | year = 2012 | doi = 10.1093/jjco/hys034 | PMID = 22450930 }}</ref>.
**May show different behaviour to other types of triple negative carcinoma
**May show different behaviour to other types of triple negative carcinoma
**May respond to different treatments
**May respond to treatments targeting the androgen receptor<ref>{{Cite journal  | last1 = Safarpour | first1 = D. | last2 = Tavassoli | first2 = FA. | title = A Targetable Androgen Receptor-Positive Breast Cancer Subtype Hidden Among the Triple-Negative Cancers. | journal = Arch Pathol Lab Med | volume =  | issue =  | pages =  | month = Oct | year = 2014 | doi = 10.5858/arpa.2014-0122-RA | PMID = 25310144 }}
</ref>


==See also==
==See also==

Revision as of 11:44, 1 April 2015

Apocrine carcinoma of the breast
Diagnosis in short
LM apocrine morphology (cells with prominent nucleoli - may be multiple, abundant granular eosinophilic cytoplasm) - must be >=90% of tumour, loss of basal cells
LM DDx glycogen-rich clear cell carcinoma of the breast
IHC AR +ve, GCDFP-15 +ve, ER -ve, PR -ve
Site breast - see invasive breast cancer
Prevalence uncommon

Apocrine carcinoma of the breast is a rare form of invasive breast cancer.

General

  • Need >=90% apocrine morphology.[1]

Microscopic

Features:[1]

  • Prominent nucleoli.
    • Often multiple.[2]
  • Abundant granular eosinophilic cytoplasm.
  • Architecture like invasive ductal carcinomas no special type.

DDx:

  • Glycogen-rich clear cell carcinoma of the breast.
  • Cutaneous Apocrine Carcinoma
      • A possible cutaneous apocrine carcinoma in a patient with a history of mammary apocrine carcinoma is problematic but fortunately a relatively infrequent conundrum.

Images

www:

  • Breast - Apocrine Carcinoma - Low power (SKB)

  • Breast - Apocrine Carcinoma - Perineural invasion - High power (SKB)

  • Breast - Apocrine Carcinoma - Low power (SKB)

  • Breast - Apocrine Carcinoma - Medium power (SKB)

  • Breast - Apocrine Carcinoma - High power (SKB)

  • Breast - Apocrine Carcinoma - High power (SKB)

IHC

Smaller tumours classically:[3]

Usually:[1]

  • ER -ve.
  • PR -ve.

Notes

  • Salivary gland carcinoma and cutaneous adnexal tumors can show a similar IHC profile.
  • Apocrine carcioma can be a non-basal type 'triple negative carcinoma' identified by both morphology and AR positivity[4].
    • May show different behaviour to other types of triple negative carcinoma
    • May respond to treatments targeting the androgen receptor[5]

See also

References

  1. ↑ 1.0 1.1 1.2 O'Malley, Frances P.; Pinder, Sarah E. (2006). Breast Pathology: A Volume in Foundations in Diagnostic Pathology series (1st ed.). Churchill Livingstone. pp. 217. ISBN 978-0443066801.
  2. ↑ O'Malley, FP.; Bane, A. (Jan 2008). "An update on apocrine lesions of the breast.". Histopathology 52 (1): 3-10. doi:10.1111/j.1365-2559.2007.02888.x. PMID 18171412.
  3. ↑ Honma, N.; Takubo, K.; Akiyama, F.; Sawabe, M.; Arai, T.; Younes, M.; Kasumi, F.; Sakamoto, G. (Aug 2005). "Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast.". Histopathology 47 (2): 195-201. doi:10.1111/j.1365-2559.2005.02181.x. PMID 16045781.
  4. ↑ Tsutsumi, Y. (May 2012). "Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.". Jpn J Clin Oncol 42 (5): 375-86. doi:10.1093/jjco/hys034. PMID 22450930.
  5. ↑ Safarpour, D.; Tavassoli, FA. (Oct 2014). "A Targetable Androgen Receptor-Positive Breast Cancer Subtype Hidden Among the Triple-Negative Cancers.". Arch Pathol Lab Med. doi:10.5858/arpa.2014-0122-RA. PMID 25310144.
Retrieved from "https://librepathology.org/w/index.php?title=Apocrine_carcinoma_of_the_breast&oldid=37271"